Stocks
Teva Pharmaceutical Industries Financial Statements (TEVA) |
||||||||||
| Teva Pharmaceutical Industriessmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 21.02.2020 | 10.02.2021 | 09.02.2022 | 10.02.2023 | 12.02.2024 | 06.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 16 887 | 16 658 | 15 878 | 14 925 | 15 846 | 16 783 | |||
| Operating Income, bln rub | 2 797 | 3 053 | 3 198 | 2 797 | 433.0 | 2 141 | ||||
| EBITDA, bln rub | ? | 1 279 | -2 094 | 4 409 | -874.0 | 4 333 | 2 025 | |||
| Net profit, bln rub | ? | -999.0 | -3 990 | 417.0 | -2 353 | -559.0 | -992.0 | |||
| OCF, bln rub | ? | 538.0 | 1 216 | 798.0 | 1 590 | 1 368 | 2 468 | |||
| CAPEX, bln rub | ? | 119.0 | 578.0 | 562.0 | 548.0 | 526.0 | 488.0 | |||
| FCF, bln rub | ? | 419.0 | 638.0 | 236.0 | 1 042 | 842.0 | 1 980 | |||
| Dividend payout, bln rub | 52.0 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 4 816 | 4 668 | 4 495 | 4 283 | 4 451 | 4 629 | ||||
| Cost of production, bln rub | 9 351 | 8 933 | 8 284 | 7 952 | 8 200 | 8 413 | ||||
| R&D, bln rub | 1 010 | 997.0 | 967.0 | 838.0 | 953.0 | 978.0 | ||||
| Interest expenses, bln rub | 822.0 | 963.0 | 1 058 | 966.0 | 1 029 | 712.0 | ||||
| Assets, bln rub | 57 470 | 50 640 | 47 666 | 44 006 | 43 479 | 41 758 | ||||
| Net Assets, bln rub | ? | 13 972 | 10 026 | 10 278 | 7 897 | 7 506 | 6 383 | |||
| Debt, bln rub | 27 342 | 26 398 | 23 459 | 21 561 | 20 153 | 19 275 | ||||
| Cash, bln rub | 1 975 | 2 177 | 2 165 | 2 801 | 3 226 | 3 319 | ||||
| Net debt, bln rub | 25 367 | 24 221 | 21 294 | 18 760 | 16 927 | 15 956 | ||||
| Ordinary share price, rub | 9.80 | 9.65 | 8.01 | 9.12 | 10.4 | 10.3 | ||||
| Number of ordinary shares, mln | 1 091 | 1 095 | 1 102 | 1 110 | 1 119 | 1 133 | ||||
| Market cap, bln rub | 10 692 | 10 567 | 8 827 | 10 123 | 11 682 | 11 670 | ||||
| EV, bln rub | ? | 36 059 | 34 788 | 30 121 | 28 883 | 28 609 | 27 626 | |||
| Book value, bln rub | -22 106 | -19 521 | -17 228 | -16 006 | -15 058 | -14 497 | ||||
| EPS, rub | ? | -0.92 | -3.64 | 0.38 | -2.12 | -0.50 | -0.88 | |||
| FCF/share, rub | 0.38 | 0.58 | 0.21 | 0.94 | 0.75 | 1.75 | ||||
| BV/share, rub | -20.3 | -17.8 | -15.6 | -14.4 | -13.5 | -12.8 | ||||
| EBITDA margin, % | ? | 7.57% | -12.6% | 27.8% | -5.86% | 27.3% | 12.1% | |||
| Net margin, % | ? | -5.92% | -24.0% | 2.63% | -15.8% | -3.53% | -5.91% | |||
| FCF yield, % | ? | 3.92% | 6.04% | 2.67% | 10.3% | 7.21% | 17.0% | |||
| ROE, % | ? | -7.15% | -39.8% | 4.06% | -29.8% | -7.45% | -15.5% | |||
| ROA, % | ? | -1.74% | -7.88% | 0.87% | -5.35% | -1.29% | -2.38% | |||
| P/E | ? | -10.7 | -2.65 | 21.2 | -4.30 | -20.9 | -11.8 | |||
| P/FCF | 25.5 | 16.6 | 37.4 | 9.72 | 13.9 | 5.89 | ||||
| P/S | ? | 0.63 | 0.63 | 0.56 | 0.68 | 0.74 | 0.70 | |||
| P/BV | ? | -0.48 | -0.54 | -0.51 | -0.63 | -0.78 | -0.80 | |||
| EV/EBITDA | ? | 28.2 | -16.6 | 6.83 | -33.0 | 6.60 | 13.6 | |||
| Debt/EBITDA | 19.8 | -11.6 | 4.83 | -21.5 | 3.91 | 7.88 | ||||
| R&D/CAPEX, % | 848.7% | 172.5% | 172.1% | 152.9% | 181.2% | 200.4% | ||||
| CAPEX/Revenue, % | 0.70% | 3.47% | 3.54% | 3.67% | 3.32% | 2.91% | ||||
| Teva Pharmaceutical Industries shareholders | ||||||||||
